Journal
ENDOCRINOLOGY
Volume 153, Issue 8, Pages 3815-3827Publisher
ENDOCRINE SOC
DOI: 10.1210/en.2012-1068
Keywords
-
Categories
Funding
- Korea Health Technology R&D Project, Ministry of Health and Welfare [A101198]
- Ministry of Education, Science, and Technology (MEST), the Republic of Korea [2011K000282, 2011K000291, 20110001692, 20110000932]
- Korea Health Promotion Institute [A101198] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
A delayed oligodendrocyte cell death after spinal cord injury (SCI) contributes to chronic demyelination of spared axons, leading to a permanent neurological deficit. Therefore, therapeutic approaches to prevent oligodendrocyte cell death after SCI should be considered. Estrogens are well known to have a broad neuroprotective effect, but the protective effect of estrogens on oligodendrocytes after injury is largely unknown. Here, we demonstrated that 17 beta-estradiol attenuates apoptosis of oligodendrocytes by inhibiting RhoA and c-Jun-N-terminal kinase activation after SCI. Estrogen receptor (ER)-alpha and -beta were expressed in oligodendrocytes of the spinal cord, and 17 beta-estradiol treatment significantly inhibited oligodendrocyte cell death at 7 d after injury as compared with vehicle (cyclodextrin) control. 17 beta-Estradiol also attenuated caspase-3 and -9 activation at 7 d and reduced the loss of axons from progressive degeneration. In addition, 17 beta-estradiol inhibited RhoA and JNK3 activation, which were activated and peaked at 3 and/or 5 d after injury. Furthermore, administration of Rho inhibitor, PEP-1-C3 exoenzyme, inhibited RhoA and JNK3 activation, and decreased phosphorylated c-Jun level at 5 d after injury. Additionally, the attenuation of RhoA and JNK3 activation as well as oligodendrocyte cell death by 17 beta-estradiol was reversed by ER antagonist, ICI182780. Our results thus indicate that 17 beta-estradiol treatment improves functional recovery after SCI in part by reducing oligodendrocyte cell death via inhibition of RhoA and JNK3 activation, which were ER dependent. Furthermore, improvement of hindlimb motor function by posttreatment of 17 beta-estradiol suggests its potential as a therapeutic agent for SCI patients. (Endocrinology 153: 3815-3827, 2012)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available